CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT03798678 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

19

Enrollment

NIH

Sponsor class

Stopped Other - Drug supply issues and withdrawal of company support.

Conditions

Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions

DRUG: Carfilzomib
DRUG: Dexamethasone
DRUG: Telaglenastat Hydrochloride

Sponsor

National Cancer Institute (NCI)